STING-activating drugs could customise cancer treatments
An imaging technique identified emerging drugs that activate the STING protein to alter metabolic pathway activity in cancer cells.
List view / Grid view
An imaging technique identified emerging drugs that activate the STING protein to alter metabolic pathway activity in cancer cells.
The new study modelled the process of capsid disassembly of the hepatitis B virus at an atomic level to help develop targeted therapies.
An NIH study used whole genome sequencing to describe three molecular subtypes of lung cancer in non-smokers, possibly improving treatments.
Stanford researchers have developed a multi-purpose “mini” CRISPR system, called CasMINI, that may be easier to deliver into human cells.
New research has uncovered a mechanism underlying cardiac hypertrophy in mice, spurring novel avenues for potential treatments.
Researchers use fast and cost-effective technology to identify the viral protein inhibitor Mpro as a potential drug against COVID-19.
Dr Ronald G Crystal, Professor and Chairman of the Department of Genetic Medicine, Weill Cornell Medical College, spoke to Drug Target Review’s Fraser Owen about his research into Alzheimer’s disease and why gene therapies represent a promising area of research for neurodegenerative conditions.
A team of researchers have reversed lung fibrosis in a mouse model, highlighting a new therapeutic target for pulmonary fibrosis.
Researchers have found a vulnerability in a developmental signalling pathway, presenting a target for paediatric low-grade glioma formation.
Researchers have developed a new method that could make enzyme replacement therapy more efficient for Pompe disease treatment.
A team have found that two DNA changes appear to predict acute lymphoblastic leukaemia, illuminating genetic understanding of the disease.
Researchers at the University of East Finland have been using skin cells to investigate pathological hallmarks in frontotemporal dementia patients.
Researchers have uncovered a signalling pathway associated with glutamatergic synapse degeneration in the brains of mice with Alzheimer’s.
A supercomputing method has revealed details of glycan “gates” on the SARS-CoV-2 Spike protein that open to allow virus entry and infection.
Researchers identified the inhibitor JQ1 as a potential drug to improve immune response to CAR T-cell therapies in leukaemia patients.